(Reuters) - The German biotech company, which estimates peak annual sales of satraplatin at $500 million, said on Monday the FDA had accepted its filing for the product, an oral drug for prostate cancer patients who fail to respond to hormone treatment.
"With the designation of priority review, we expect an action on the application from the FDA in August of this year and are thus moving forward with commercialisation plans for satraplatin," GPC said in a statement.
Read more at Reuters.com Government Filings News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment